Siamab Therapeutics to Present at the 2017 BIO International Convention

Siamab Therapeutics to Present at the 2017 BIO International Convention

Siamab Therapeutics, Inc., a biopharmaceutical company developing novel cancer immunotherapies targeting tumor-associated carbohydrate antigens (TACAs), today announced that Jeff Behrens, president and chief executive officer, will present at the 2017 BIO International Convention. Read more >>

Share this post